[Ten years progression-free survival obtained in a patient with mantle cell lymphoma].

Autor:	Wysokińska E; St. John's Cancer Center, Lublin, Poland., Kolak A; St. John's Cancer Center, Lublin, Poland., Starosławska E; St. John's Cancer Center, Lublin, Poland., Kieszko D; St. John's Cancer Center, Lublin, Poland., Kamińska M; St. John's Cancer Center, Lublin, Poland., Surdyka D; St. John's Cancer Center, Lublin, Poland., Mocarska A; St. John's Cancer Center, Lublin, Poland., Burdan F; St. John's Cancer Center, Lublin, Poland.
Jazyk:	polština
Zdroj:	Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego [Pol Merkur Lekarski] 2015 May; Vol. 38 (227), pp. 280-2.
Abstrakt:	Mantle cell lymphoma is a rare aggressive lymphoma derived from B cells, characterized by rapid progression and subsequent recurrence. It is considered to be an incurable disease, with exception of a certain group of patients treated with an autogenic stem cell transplantation. The mean survival time is three years, after applying the conventional regimen based on COP (cyclophosphamide, vincristine, prednisone) or CHOP chemotherapy (COP + doxorubicin). An addition of rituximab to CHOP regimen significantly prolongs progression-free survival. The present case reports ten years progression-free survival in a female patient with mantle cell lymphoma with baseline clinical stage IVB (MIPI 5), treated with nine courses of CHOP chemotherapy. Rituximab was added from 3 to 8 course. The complete clinical, radiological and histopathological response has been obtained. (© 2015 MEDPRESS.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu